BEYONDSPRING INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.675 USD | -5.64% |
|
+8.30% | +197.22% |
| May. 15 | Transcript : BeyondSpring Inc. - Special Call | |
| Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 1.35 | Sales 2023 | 1.75 | Capitalization | 35.1M |
|---|---|---|---|---|---|
| Net income 2022 | -33M | Net income 2023 | -21M | EV / Sales 2022 | 30,256,712 x |
| Net cash position 2022 | 32.31M | Net cash position 2023 | 4.01M | EV / Sales 2023 | 17,757,074 x |
| P/E ratio 2022 |
-2.21
x | P/E ratio 2023 |
-1.67
x | Employees | 36 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on BeyondSpring Inc.
More recommendations
More press releases
| 1 day | -5.64% | ||
| 1 week | +8.30% | ||
| Current month | +33.08% | ||
| 1 month | +48.61% | ||
| 3 months | +101.13% | ||
| 6 months | +194.60% | ||
| Current year | +197.22% |
1 week
2.41
2.99
1 month
1.732.99
Current year
0.784.00
1 year
0.654.00
3 years
0.5433.00
5 years
0.5433.00
10 years
0.5448.49
| Managers | Title | Age | Since |
|---|---|---|---|
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Fabbio
BRD | Director/Board Member | 56 | 18-01-01 |
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
Matthew Kirkby
BRD | Director/Board Member | 55 | 16-10-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2.675 | -5.64% | 41,965 |
| 24-05-16 | 2.835 | +0.18% | 23,408 |
| 24-05-15 | 2.83 | +5.99% | 51,725 |
| 24-05-14 | 2.67 | +3.49% | 32,867 |
| 24-05-13 | 2.58 | +4.45% | 20,864 |
Delayed Quote Nasdaq, May 17, 2024 at 04:30 pm EDT
More quotes
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Calendar
2024-06-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +197.22% | 104M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- BYSI Stock
